7α-hydroxy-17-oxoandrost-5-ene-3β-yl acetate | 37976-94-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 7α-hydroxy-17-oxoandrost-5-ene-3β-yl acetate
• 英文别名: 7α-hydroxy-17-oxoandrost-5en-3β-yl acetate；3β-acetoxy-7α-hydroxyandrost-5-en-17-one；[(3S,7S,8R,9S,10R,13S,14S)-7-hydroxy-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] acetate
• CAS: 37976-94-6
• 化学式: C₂₁H₃₀O₄
• 分子量: 346.467
• InChiKey: ROQJNRDLUNFGNK-MXRBDKCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7α-hydroxy-17-oxoandrost-5-ene-3β-yl acetate 在 sodium carbonate 作用下， 以 甲醇 为溶剂， 反应 0.75h， 生成 7-羟基去氢表雄酮
  参考文献：
  名称：

  Ergosteroids II: Biologically Active Metabolites and Synthetic Derivatives of Dehydroepiandrosterone 11This work was supported by Humanetics Corp., St. Louis Park, Minnesota.

  摘要：

  An improved procedure for the synthesis of 3 beta-hydroxyandrost-5-ene-7, 17-dione, a natural metabolite of dehydroepiandrosterone (DHEA) is described. The synthesis and magnetic resonance spectra of several other related steroids are presented. Feeding dehydroepiandrosterone to rats induces enhanced formation of several liver enzymes among which are mitochondrial sn-glycerol 3-phosphate dehydrogenase (GPDH) and cytosolic malic enzyme. The induction of these two enzymes, that complete a thermogenic system in rat liver, was used as an assay to search for derivatives of DHEA that might be more active than the parent steroid. Activity is retained in steroids that are reduced to the corresponding 17 beta-hydroxy derivative, or hydroxylated at 7 alpha or 7 beta, and is considerably enhanced when the 17-hydroxy or 17-carbonyl steroid is converted to the 7-oxo derivative. Several derivatives of DHEA did not induce the thermogenic enzymes whereas the corresponding 7-oxo compounds did. Both short and long chain acyl esters of DHEA and of 7-oxo-DHEA are active inducers of the liver enzymes when fed to rats. 7-Oxo-DHEA-3-sulfate is as active as 7-oxo-DHEA or its 3-acetyl ester, whereas DHEA-3-sulfate is much less active than DHEA. Among many steroids tested, those posessing a carbonyl group at position 3, a methyl group at 7, a hydroxyl group at positions 1, 2, 4, 11, or 19, or a saturated B ring, with or without a 4-5 double bond, were inactive. (C) 1998 by Elsevier Science Inc.

  DOI：

  10.1016/s0039-128x(97)00159-1
• 作为产物：
  描述：

  Acetic acid (3S,8R,9S,10R,13S,14S)-7-bromo-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 在 silver(I) acetate 、 溶剂黄146 、 lithium bromide 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 0.5h， 生成 7α-hydroxy-17-oxoandrost-5-ene-3β-yl acetate
  参考文献：
  名称：

  Ergosteroids II: Biologically Active Metabolites and Synthetic Derivatives of Dehydroepiandrosterone 11This work was supported by Humanetics Corp., St. Louis Park, Minnesota.

  摘要：

  An improved procedure for the synthesis of 3 beta-hydroxyandrost-5-ene-7, 17-dione, a natural metabolite of dehydroepiandrosterone (DHEA) is described. The synthesis and magnetic resonance spectra of several other related steroids are presented. Feeding dehydroepiandrosterone to rats induces enhanced formation of several liver enzymes among which are mitochondrial sn-glycerol 3-phosphate dehydrogenase (GPDH) and cytosolic malic enzyme. The induction of these two enzymes, that complete a thermogenic system in rat liver, was used as an assay to search for derivatives of DHEA that might be more active than the parent steroid. Activity is retained in steroids that are reduced to the corresponding 17 beta-hydroxy derivative, or hydroxylated at 7 alpha or 7 beta, and is considerably enhanced when the 17-hydroxy or 17-carbonyl steroid is converted to the 7-oxo derivative. Several derivatives of DHEA did not induce the thermogenic enzymes whereas the corresponding 7-oxo compounds did. Both short and long chain acyl esters of DHEA and of 7-oxo-DHEA are active inducers of the liver enzymes when fed to rats. 7-Oxo-DHEA-3-sulfate is as active as 7-oxo-DHEA or its 3-acetyl ester, whereas DHEA-3-sulfate is much less active than DHEA. Among many steroids tested, those posessing a carbonyl group at position 3, a methyl group at 7, a hydroxyl group at positions 1, 2, 4, 11, or 19, or a saturated B ring, with or without a 4-5 double bond, were inactive. (C) 1998 by Elsevier Science Inc.

  DOI：

  10.1016/s0039-128x(97)00159-1

文献信息

• MnO₂/TBHP: A Versatile and User-­Friend­ly Combination of Reagents for the Oxidation of Allylic and Benzylic Methylene Functional Groups
  作者：Stefano Serra

  DOI：10.1002/ejoc.201500829

  日期：2015.9

  activated MnO2, tert-butyl hydroperoxide (TBHP) in CH2Cl2 is able to oxidize the allylic and benzylic methylene groups of different classes of compounds. I describe a one-pot oxidation protocol based on two sequential steps. In the first step, carried out at low temperature, MnO2 catalyses the oxidation of the methylene group. This is followed by a second step where reaction temperature is increased

  在活化的 MnO2 存在下，CH2Cl2 中的叔丁基过氧化氢 (TBHP) 能够氧化不同类别化合物的烯丙基和苄基亚甲基。我描述了基于两个连续步骤的一锅氧化方案。在低温下进行的第一步中，MnO2 催化亚甲基的氧化。这之后是第二步，其中反应温度升高，使 MnO2 既可以催化未反应的 TBHP 分解，又可以氧化可能形成的烯丙醇。所提出的氧化程序通常适用，尽管其效率、区域选择性和化学选择性在很大程度上取决于底物的结构。
• Stereoselective 7.ALPHA.-Hydroxylation of 3.BETA.-Acetoxy-.DELTA.5-steroids by Fe(PA)3/H2O2/MeCN.
  作者：Eiichi KOTANI、Tetsuya TAKEYA、Hirotaka EGAWA、Seisho TOBINAGA

  DOI：10.1248/cpb.45.750

  日期：——

  Stereoselective 7α-hydroxylation reaction of Δ5-steroids by a Fe(PA; picolinate)3/H2O2/MeCN system is presented. The 7α-hydroxylation reactions were achieved in 33-40% yields by addition of 30%-H2O2 to a solution of 3β-acetoxy-Δ5-steroids 1a-1d and a crystalline of Fe(PA)3 in MeCN.

  通过Fe(PA; 皮考林酸盐)3/H2O2/MeCN体系实现了Δ5类固醇的立体选择性7α-羟基化反应。通过将30%-H2O2添加到含有3β-乙酰氧基-Δ5类固醇1a-1d和Fe(PA)3的MeCN溶液中，该反应的产率达到了33-40%。
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• Compositions and treatment methods
  申请人：Ahlem N. Clarence

  公开号：US20060079492A1

  公开（公告）日：2006-04-13

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。
• COMPOSITIONS AND TREATMENT METHODS-2
  申请人：Frincke James M.

  公开号：US20100222425A1

  公开（公告）日：2010-09-02

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可以在本发明中使用的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄烷。这些化合物可以用于治疗方法中。